Johnson & Johnson's Tremfya Achieves Key Endpoints in Psoriatic Arthritis Study

MT Newswires Live04-04

Johnson & Johnson (JNJ) said Friday that its experimental drug, Tremfya, met primary and major secondary endpoints in a phase 3 study for adults with active psoriatic arthritis.

The company said Tremfya reduced signs and symptoms of active psoriatic arthritis and significantly minimized the progression of structural damage, as measured by radiographic progression at 24 weeks, compared to a placebo.

In the phase 3 study, the company said patients treated with Tremfya also showed significantly less structural damage progression, as assessed by the active psoriatic arthritis modified van der Heijde-Sharp score, which measures joint space narrowing and erosion.

The data was consistent with Tremfya's safety profile, with no new safety concerns identified, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment